Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium chloride solution 0.9% (saline) Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

NCT06483659
View directory record Official record
Conditions
Postoperative Pain
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 13, 2026, 8:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis

NCT03639779
View directory record Official record
Conditions
Calcinosis Cutis
Interventions
Sodium Thiosulfate, Saline Solution
Drug · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 13, 2026, 8:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions

NCT02413125
View directory record Official record
Conditions
Sinusitis
Interventions
ChitoRhino irrigation solution, Normal saline
Device · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

NCT07701590
View directory record Official record
Conditions
Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions
Microlyte®, IP 1: Membrane Wrap - Hydro
Device
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Solution Temperature and Fluid Deficit During Hysteroscopy

NCT05622097
View directory record Official record
Conditions
Surgery
Interventions
0.9% Saline warmed to 37 degrees Celsius, 0.9% Saline warmed to 24 degrees Celsius
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

NCT06096597
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)
Interventions
Clarix Flo, Placebo
Drug
Lead sponsor
David Sheyn
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Clevleand, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Results available

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
(Bupivacaine Liposome Injectable Suspension), Standard Preparation
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Early Phase 1 Interventional

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

NCT03777215
View directory record Official record
Conditions
Obesity
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819
View directory record Official record
Conditions
HIV-1-infection
Interventions
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional

Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia

NCT01438398
View directory record Official record
Conditions
Achalasia, Dysphagia
Interventions
Submucosal endoscopic myotomy with mucosal flap technique, Submucosal Endoscopic Mucosal Flap (SEMF) technique
Procedure
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 13, 2026, 8:34 PM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00348608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 13, 2026, 8:34 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Tranexamic Acid in Adherent Placenta (TAP)

NCT02329756
View directory record Official record
Conditions
Placenta Accreta
Interventions
Tranexamic Acid (TXA), Sodium Chloride 0.9%
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional

Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery

NCT00494832
View directory record Official record
Conditions
Spine Surgery
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 13, 2026, 8:34 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Vasopressin on Glucose Regulation

NCT02761434
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hypertonic Saline (3% NaCl), Isotonic Saline (0.9% NaCl)
Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Results available

Cognitive Enhancement in Depression (The COG-D Study)

NCT05400512
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptom
Interventions
Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
paclitaxel, TAK-228, TAK-117
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Results available

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

NCT01939145
View directory record Official record
Conditions
Wound Infection
Interventions
Normal saline, Prontosan
Drug · Device
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Phase 3 Interventional

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

NCT05470205
View directory record Official record
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Prick Test of KeraStat® Cream

NCT04058054
View directory record Official record
Conditions
Hypersensitivity
Interventions
KeraStat® Cream, KeraStat Gel, Biafine, Histamine, Saline (0.9% NaCl)
Device · Drug
Lead sponsor
KeraNetics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 13, 2026, 8:34 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 13, 2026, 8:34 PM EDT